NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES OF AMERICA, CANADA, JAPAN OR AUSTRALIA OR ANY OTHER JURISDICTION IN WHICH THE RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL.
Ad hoc announcement pursuant to Art. 53 LR of the Swiss stock exchange SIX
Bachem launches an accelerated bookbuilding for the placement of approx. 750’000 new shares to finance its growth plan
- Share placement of approx. 750’000 new shares via an accelerated bookbuilding authorized by the extraordinary general shareholder meeting held on October 15, 2021, and representing approx. 5% of currently issued share capital.
- Bachem intends to deploy the funds to accelerate capacity expansion across all sites and the construction of an additional manufacturing site in Switzerland.
- Upon completion, the capital increase will enhance the trading liquidity of Bachem shares and expand the shareholder base.
About Bachem
Bachem is a leading, innovation-driven company specializing in the development and manufacture of peptides and oligonucleotides.
With 50 years of experience and expertise Bachem provides products for research, clinical development and commercial application to pharmaceutical and biotechnology companies worldwide and offers a comprehensive range of services.
Bachem operates internationally with headquarters in Switzerland and locations in Europe, the US and Asia. The company is listed on the SIX Swiss Exchange.
Press release in English
Press release in German
For more information:
Bachem Holding AG
Dr. Daniel Grotzky
Head Group Communications
Media: media[at]bachem.com
Investors: ir[at]bachem.com